341
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Long-Term Intravitreal Dexamethasone Implant Outcomes in Uveitis

, MD, PhDORCID Icon, , MD, PhDORCID Icon, , , MD, PhDORCID Icon, , MD, PhDORCID Icon & , MD, PhD
Pages 228-237 | Received 02 Aug 2018, Accepted 31 Jan 2019, Published online: 17 Apr 2019

References

  • Pelegrín L, Sainz de la Maza M, Molins B, Ríos J, Adán A. Long-term evaluationof dexamethasone intravitreal implant invitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveítis. Eye (Lond). 2015;29(7):943–950. doi:10.1038/eye.2015.73.
  • Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina. 2006;26(suppl):1–16. doi:10.1097/01.iae.0000250601.15893.5f.
  • Rhee DJ, Katrhyn A, Sobrin CL, Rapuano CJ. Ophthalmic Drug Guide. 2nd ed. London: Springer New York Dordrecht Heidelberg; 2011.
  • De Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452–470. doi:10.1016/j.preteyeres.2011.06.005.
  • Zola M, Briamonte C, Lorenzi U, et al. Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone. ClinOphthalmol. Nov 2017;6(11):1949–1956.
  • Hunter R, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. ClinOphthalmol. 2011;5:1613–1621.
  • Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Delivery. 2008;5(9)::1039–1046. doi:10.1517/17425247.5.9.1039.
  • Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for non infectious intermediate or posterior uveitis.Ozurdex HURON study group. Arch Ophthalmol. May 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339.
  • Pohlmann D, Vom Brocke GA, Winterhalter S, Steurer T, Thees S, Pleyer U. Dexamethasone inserts in noninfectious Uveitis: A single-center experience. Ophthalmology. 2018;125(17):31574–31579. doi:10.1016/j.ophtha.2017.12.038.
  • Palla S, Biswas J, Naesha CK. Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis. Indian J Ophthalmol. 2015 Oct;63(10):767–770. doi:10.4103/0301-4738.171505.
  • De Smet MD. Corticosteroid intravitreal implants. Dev Ophthalmol. 2012;51(1):122–133. doi:10.1159/000336330.
  • Lange C, Feltgen N, Junker B, et al. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137–142. doi:10.1007/s00417-008-0926-0.
  • Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0.
  • Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121(8):1649–1654. doi:10.1016/j.ophtha.2014.02.003.
  • Bajwa A, Peck T, Reddy AK, Netland PA, Shidkrot Y. Dexamethasone implantation in birdshot chorioretinopathy-long-term outcome. Int Med Case Rep J. 2018;30(11):349–358. doi:10.2147/IMCRJ.S164206.
  • Pohlman D, Winterhalter S, Pleyer U. Intravitreal dexamethasone for the treatment of CMO associated with refractory Sclerouveitis. Ocul Immunol Inflamm. 2018;26(1):160–165. doi:10.1080/09273948.2016.1196712.
  • Frere A, Caspers L, Makhoul D, Judice L. Single dexamethasone intravitreal implant in the treatment of noninfectious Uveitis. JOculPharmacolTher. May 2017;33(4):290–297.
  • Ratra D, Barh A, Banerjee M, et al. Safety and efficacy of intravitreal dexamethasone implant for refractory uveitic macular edemain adults and children. Ocul Immunol Inflamm. 2018;26(7):1034–1040. doi:10.1080/09273948.2018.1424342.
  • Garweg JG, Baglivo E, Freiberg FJ, et al. Response of postoperative and chronic uveitic cystoid macular Edema to a dexamethasone-based intravitrea implant (Ozurdex). J Ocul Pharmacol Ther. Sep 2016;32(7):442–450.
  • Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implantin noninfectious Uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. Dec 2014;158(6):1136–1145. doi:10.1016/j.ajo.2014.09.003.
  • Malcle A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (ozurdex): the safodex study:. Incidence and risk factors of ocular hypertension. Retina. 2017;37(4):1352–1359. doi:10.1097/IAE.0000000000001369.
  • Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm. 2017;25(6):834–840. doi:10.1080/09273948.2016.1184284.
  • Breitbach M, Rack D, Dietzel M, et al. Efficacy of a dexamethasone implant for the treatment of refractory cystoid macular edema in non-infectious uveitis. Klin Monbl Augenheilkd. May 2016;233(5):601–605. doi:10.1055/s-0042-102058.
  • Fonollosa A, Llorenç V, Artaraz J, et al. Safety and efficacy of intravitreal dexamethasone implants in the management of macular edema secondary to infectious uveitis. Retina. Sep 2016;36(9):1778–1785. doi:10.1097/IAE.0000000000001001.
  • Tsang AC, Virgili G, Abtahi M, et al. Intravitreal dexamethasone implant for the treatment of macular edema in chronic non-infectious Uveitis. Ocul Immunol Inflamm. Oct 2017;25(5):685–692. doi:10.3109/09273948.2016.1160130.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.